Abstract 2474
Background
Uveal melanoma is the most common primary intraocular malignancy in adults. Almost half of patients with uveal melanoma may die from metastatic disease and the most frequent site of metastases is the liver. It is considered as an inflammatory phenotype. NFκB plays a connecting link between the inflammation and cancer. c-Rel and p50 are together considered as a heterodimer (c-Rel/p50) which plays an important role in inflammation and cancer progression. Therefore, the aim of the study is to detect c-Rel/p50 heterodimer expression in the tumour microenvironment of uveal melanoma and its prognostic significance.
Methods
Evaluation of c-Rel/p50 heterodimer expression was performed in 75 formalin fixed uveal melanoma tissues by using immunohistochemistry. Transcriptional analysis was performed on 58 fresh tissues by real-time PCR (q-PCR). Co-Immunoprecipitation (Co-IP) was done on 10 representative cases to assess the presence of c-Rel/p50 heterodimer and validation of immunohistochemistry results was performed by western blotting. Results were then correlated with clinicopathological parameters.
Results
Immunoexpression of c-Rel+/p50+ is localized to the cytoplasm in normal choroid whereas both cytoplasmic and nuclear expression was seen in 33.33% cases. At the transcriptional level, upregulation of c-Rel+/p50+ heterodimer was shown in 43.10%. Expression of both cytoplasmic and nuclear c-Rel+/p50+ heterodimer were found to have significant correlation with cases having tumour infiltrating lymphocytes, macrophages (CD68+) and high pigmentation. There was a statistically significant difference in the overall survival of patients with nuclear and cytoplasmic expression of c-Rel+/p50+ heterodimer (p < 0.05).
Conclusions
We conclude that c-Rel+/p50+ heterodimer may be used as a poor prognostic indicator of survival outcome in uveal melanoma. Further translational and validation studies are required to confirm its usage as a therapeutic drug target in metastatic uveal melanoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3683 - Impact of Radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
Presenter: Evangeline Samuel
Session: Poster Display session 1
Resources:
Abstract
3924 - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real World Data from a European Cohort with focus on subgroups of interest
Presenter: Giannis Mountzios
Session: Poster Display session 1
Resources:
Abstract
3970 - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Martin Sebastian
Session: Poster Display session 1
Resources:
Abstract
5350 - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Presenter: Motohiro Tamiya
Session: Poster Display session 1
Resources:
Abstract
3832 - Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)
Presenter: Giulio Metro
Session: Poster Display session 1
Resources:
Abstract
4082 - Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
Presenter: Riyaz Shah
Session: Poster Display session 1
Resources:
Abstract
2855 - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumor DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global Ph3 study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations
Presenter: Kazuto Nishio
Session: Poster Display session 1
Resources:
Abstract
2911 - Apatinib combined with EGFR - TKI in treating advanced non-small cell lung cancer with EGFR - TKI resistance
Presenter: Ruifen Tian
Session: Poster Display session 1
Resources:
Abstract
2100 - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Presenter: Takashi Ninomiya
Session: Poster Display session 1
Resources:
Abstract
4325 - Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: insights of the MATCH-R study
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract